Efficacy and safety exposure –response analyses of entrectinib in patients with advanced or metastatic solid tumors

ConclusionThese analyses supported that entrectinib at 600  mg/day provides an acceptable benefit–risk ratio in adults withNTRK-,ROS1-, orALK-positive tumors, considered as rare disease.

Source: Cancer Chemotherapy and Pharmacology - February 3, 2022 Category: Cancer & Oncology Source Type: research